Vilazodon
 | |
| IUPAC ime | |
|---|---|
5-(4-[4-(5-cijano-1H-indol-3-il)butil]piperazin-1-il)benzofuran-2-karboksamid | |
| Klinički podaci | |
| Prodajno ime | Viibryd |
| Drugs.com | Potrošačka informacije o leku |
| MedlinePlus | a611020 |
| Podaci o licenci | |
| Kategorija trudnoće |
|
| Način primene | Oralno |
| Pravni status | |
| Pravni status |
|
| Farmakokinetički podaci | |
| Poluvreme eliminacije | 20-24 sata |
| Identifikatori | |
| CAS broj | 163521-12-8  |
| ATC kod | N06AX24 (WHO) |
| PubChem | CID 6918313 |
| ChemSpider | 5293518 |
| UNII | S239O2OOV3 |
| KEGG | D09698 |
| ChEMBL | CHEMBL439849 |
| Hemijski podaci | |
| Formula | C26H27N5O2 |
| Molarna masa | 441,524 g/mol |
| |
| |
Vilazodon (Viibryd) je serotinergički antidepresiv koji je razvijen za tretman kliničke depresije.[1] FDA je odobrila upotrebu vilazodona 2011.[2][3][4]
Farmakologija
[уреди | уреди извор]Vilazodon deluje kao inhibitor preuzimanja serotonina (IC50 = 0.5 nM) i parcijalni agonist 5-HT1A receptora (IC50 = 0.2 nM; IA = ~60-70%).[5][6] On ima neznatan afinitet za druge serotoninske receptore kao što je 5-HT1D, 5-HT2A, i 5-HT2C.[5][6]
References
[уреди | уреди извор]- ^ de Paulis T (2007). „Drug evaluation: Vilazodone--a combined SSRI and 5-HT1A partial agonist for the treatment of depression”. IDrugs : the Investigational Drugs Journal. 10 (3): 193—201. PMID 17351874.
- ^ „FDA approves Clinical Data Inc's antidepressant”. Reuters. 22. 1. 2011.
- ^ „FDA approves Clinical Data Inc's antidepressant”. Reuters. 22. 1. 2011.
- ^ „Clinical Data, Inc. - Clinical Data, Inc. Submits New Drug Application for Vilazodone for the Treatment of Major Depressive Disorder”. Архивирано из оригинала 18. 08. 2011. г.
- ^ а б Page ME; Cryan JF; Sullivan A; et al. (2002). „Behavioral and neurochemical effects of 5-(4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl)-benzofuran-2-carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine(1A) receptor partial agonist”. The Journal of Pharmacology and Experimental Therapeutics. 302 (3): 1220—7. PMID 12183683. doi:10.1124/jpet.102.034280.
- ^ а б Hughes ZA; Starr KR; Langmead CJ; et al. (2005). „Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone”. European Journal of Pharmacology. 510 (1–2): 49—57. PMID 15740724. doi:10.1016/j.ejphar.2005.01.018.
